Browse by author
Lookup NU author(s): Dr Kate HallsworthORCiD, Dr Kieren Hollingsworth, Dr Christian Thoma, Professor Djordje JakovljevicORCiD, Dr Guy MacGowanORCiD, Professor Quentin AnsteeORCiD, Professor Roy Taylor, Professor Chris Day, Professor Mike TrenellORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Background & Aims: Non-alcoholic fatty liver disease (NAFLD) is associated with a twofold greater risk of developing cardiovascular disease. Despite this, little is known about the effect of NAFLD upon cardiac function, limiting our ability to identify therapeutic strategies. This study aimed to address this by defining the effect of NAFLD on cardiac function, structure, and metabolism. Methods: Nineteen adults with NAFLD were age-, sex-, and BMI-matched to healthy controls without liver or metabolic disease. Cardiac structure and function were assessed using high-resolution cardiac MRI and tagging at 3.0 T. High-energy phosphate metabolism was assessed using 31P-magnetic resonance spectroscopy to measure the PCr/ATP ratio. Results: Adults with NAFLD had significantly thicker left ventricular walls at systole (14 ± 3 vs. 12 ± 2 mm; p <0.01) and diastole (8 ± 1 vs. 7 ± 1 mm; p <0.01) than those without fatty liver and showed decreased longitudinal shortening (14 ± 3 vs. 17 ± 3%; p <0.01). The eccentricity ratio was significantly higher in the NAFLD group (1.1 ± 0.2 vs. 0.9 ± 0.2 g/ml; p <0.01) indicating concentric remodelling. Peak whole wall strain was higher in the NAFLD group (19 ± 2 vs. 17 ± 3%; p <0.01), as was peak endocardial strain (28 ± 4 vs. 22 ± 5%; p <0.01). Cardiac metabolism, measured by PCr/ATP ratio, was not altered in NAFLD (1.8 ± 0.3 vs. 1.9 ± 0.3; p = 0.36). Conclusions: Significant changes in cardiac structure and function are evident in adults with NAFLD in the apparent absence of metabolic changes or overt cardiac disease. Clinicians should continue to explore therapies to improve cardiac function as a means to modify the excess risk of cardiovascular disease associated with NAFLD.
Author(s): Hallsworth K, Hollingsworth KG, Thoma C, Jakovljevic DG, MacGowan GA, Anstee QM, Taylor R, Day CP, Trenell MI
Publication type: Article
Publication status: Published
Journal: Journal of Hepatology
Year: 2013
Volume: 58
Issue: 4
Pages: 757-762
Print publication date: 01/04/2013
Online publication date: 22/11/2012
Acceptance date: 07/11/2012
ISSN (print): 0168-8278
ISSN (electronic): 1600-0641
Publisher: Elsevier
URL: http://dx.doi.org/10.1016/j.jhep.2012.11.015
DOI: 10.1016/j.jhep.2012.11.015
Altmetrics provided by Altmetric